| Expression pattern: |
UP |
| Associated gene: |
- |
| Associated microRNA: |
hsa-miR-18a-5p, hsa-miR-18b-5p, hsa-miR-149-5p, hsa-miR-30e-5p, hsa-miR-6871-5p, hsa-miR-6751-5p, hsa-miR-6803-5p, hsa-miR-194-3p, hsa-miR-622, hsa-miR-21-3p, hsa-miR-592, hsa-miR-516a-3p, hsa-miR-516b-3p, hsa-miR-4441 |
| Biological function: |
Potential plasma biomarker; inferred involvement in AD-related biological processes and pathways via predicted miRNA targets (brain-enriched targets; nervous system development, apoptosis and inflammatory processes). |
| Molecular mechanism: |
Predicted circRNA-miRNA-mRNA regulatory network (TargetScan/miRanda; miRTarBase targets) with enrichment analysis; no wet-lab validation of specific miRNA binding reported. |
| Biological pathway or process: |
ceRNA regulation (other); apoptosis (other); inflammation (other pathway/process); AMPK (other); MAPK (other); PI3K/AKT/mTOR (other); other pathway/process (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RNase R Treatment; RT-qPCR; Clinical Sample Validation; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
ROC analysis showed fair diagnostic accuracy for distinguishing AD from healthy controls (AUC 0.710). |
| Description: |
hsa_circRNA_003022 (PITRM1 locus) is increased in plasma from AD patients and also elevated in MCI vs controls. The work models it within a predicted circRNA-miRNA-mRNA network, with multiple shared miRNAs, and links its putative targets to AD-relevant processes via enrichment analyses. |
| Confidence score: |
0.5963 |